Microsoft (MSFT) hits rare value after a 25% drop. Explore fundamentals, MSFU 2x ETF risks, and entry signals—read now and ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and ...

As a coach, investor, and Chairman of the Napoleon Hill Institute, I’ve seen careers ...

Texas Roadhouse, Inc. is rated a Buy due to consistent profitable expansion, robust comps, and reasonable valuation. Learn ...

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures ...

Three AI accelerators deliver decision-ready intelligence that integrates directly into existing operational systems ...

HealthDay News — Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.

Key Takeaways On Feb. 6, 2026, FDA announced that it would take action to restrict access to GLP-1 ingredients for non-FDA ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling ...

The maker of Ozempic and Wegovy is suing a rival firm for selling what it says are "unsafe, knock-off" versions of its weight ...

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...

A K-shaped economy that lasts long enough results in a top that grows careless, a bottom that grows combustible, and the ...